Cargando…

Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts

BACKGROUND/INTRODUCTION: Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines. METHODS: To a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, István, Kovács, Edit, Zádori, Zoltán, Mészáros, István, Cságola, Attila, Bajnóczi, Pál, Mortensen, Preben, Palya, Vilmos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048948/
https://www.ncbi.nlm.nih.gov/pubmed/32158645
http://dx.doi.org/10.2147/VMRR.S236912
_version_ 1783502370317008896
author Kiss, István
Kovács, Edit
Zádori, Zoltán
Mészáros, István
Cságola, Attila
Bajnóczi, Pál
Mortensen, Preben
Palya, Vilmos
author_facet Kiss, István
Kovács, Edit
Zádori, Zoltán
Mészáros, István
Cságola, Attila
Bajnóczi, Pál
Mortensen, Preben
Palya, Vilmos
author_sort Kiss, István
collection PubMed
description BACKGROUND/INTRODUCTION: Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines. METHODS: To address this question, vaccinated pregnant gilts were challenged with a PPV-27a-like virus strain and parameters related to vaccine efficacy were compared. RESULTS: The K22 vaccine strain of Parvoruvax(®) (PVX) was characterized as “Kresse-like” based on the epitope mapping data. Vaccination of the gilts induced a low level of antibody responses. Based on foetal mortality, the number of sows which had challenge virus-affected foetuses, the percent of PPV positive piglets/litters plus their PPV genome and viral load PVX outscored the other vaccinated groups. CONCLUSION: Stronger protection was provided by the “Kresse-like” K22 PPV strain-based vaccine than by the NADL-2 and NADL-like strain-based commercial vaccines against a PPV-27a cluster strain challenge. Vaccine-induced antibody levels as measured pre-challenge were not found to be an accurate indicator of protection.
format Online
Article
Text
id pubmed-7048948
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70489482020-03-10 Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts Kiss, István Kovács, Edit Zádori, Zoltán Mészáros, István Cságola, Attila Bajnóczi, Pál Mortensen, Preben Palya, Vilmos Vet Med (Auckl) Original Research BACKGROUND/INTRODUCTION: Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines. METHODS: To address this question, vaccinated pregnant gilts were challenged with a PPV-27a-like virus strain and parameters related to vaccine efficacy were compared. RESULTS: The K22 vaccine strain of Parvoruvax(®) (PVX) was characterized as “Kresse-like” based on the epitope mapping data. Vaccination of the gilts induced a low level of antibody responses. Based on foetal mortality, the number of sows which had challenge virus-affected foetuses, the percent of PPV positive piglets/litters plus their PPV genome and viral load PVX outscored the other vaccinated groups. CONCLUSION: Stronger protection was provided by the “Kresse-like” K22 PPV strain-based vaccine than by the NADL-2 and NADL-like strain-based commercial vaccines against a PPV-27a cluster strain challenge. Vaccine-induced antibody levels as measured pre-challenge were not found to be an accurate indicator of protection. Dove 2020-02-24 /pmc/articles/PMC7048948/ /pubmed/32158645 http://dx.doi.org/10.2147/VMRR.S236912 Text en © 2020 Kiss et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kiss, István
Kovács, Edit
Zádori, Zoltán
Mészáros, István
Cságola, Attila
Bajnóczi, Pál
Mortensen, Preben
Palya, Vilmos
Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
title Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
title_full Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
title_fullStr Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
title_full_unstemmed Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
title_short Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
title_sort vaccine protection against experimental challenge infection with a ppv-27a genotype virus in pregnant gilts
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048948/
https://www.ncbi.nlm.nih.gov/pubmed/32158645
http://dx.doi.org/10.2147/VMRR.S236912
work_keys_str_mv AT kissistvan vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts
AT kovacsedit vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts
AT zadorizoltan vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts
AT meszarosistvan vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts
AT csagolaattila vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts
AT bajnoczipal vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts
AT mortensenpreben vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts
AT palyavilmos vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts